Co-culture of cord blood CD34+ cells with human BM mesenchymal stromal cells enhances short-term engraftment of cord blood cells in NOD/SCID mice

Cytotherapy ◽  
2007 ◽  
Vol 9 (4) ◽  
pp. 338-347 ◽  
Author(s):  
X.M. Fei ◽  
Y.J. Wu ◽  
Z. Chang ◽  
K.R. Miao ◽  
Y.H. Tang ◽  
...  
2014 ◽  
Vol 93 (5) ◽  
pp. 384-391 ◽  
Author(s):  
Luisa Milazzo ◽  
Francesca Vulcano ◽  
Alessandra Barca ◽  
Giampiero Macioce ◽  
Emanuela Paldino ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2701-2701
Author(s):  
Akihito Fujimi ◽  
Takuya Matsunaga ◽  
Masayoshi Kobune ◽  
Yutaka Kawano ◽  
Ikuta Tanaka ◽  
...  

Abstract New sources of red blood cells (RBC) would improve the transfusion capacity of blood centers. Several investigators have previously reported that erythroblasts could be obtained from hematopoietic stem cells including those of cord blood (CB) by in vitro culture. However, transfusion of erythroblasts may not be suitable for supplementation of acute blood loss because it should need some time lag until hemoglobin (RBC) boost in circulation due to the fact that transfused erythroblasts once lodged at bone marrow where they undergo maturation into RBCs which are bound to be released into circulation. We have developed a culture system for producing large quantity of enucleated RBCs (e-RBCs) as well as erythroblasts from CB in vitro: one unit e-RBCs (2 x 1012 RBCs) was obtained from one standard CB unit (corresponding to 2 x 106 CD34+ cells) using a coculture system with hTERT-transfected human stromal cells at early phase followed by with activated macrophage in liquid culture (American Society of Hematology 45th Annual Meeting, SanDiego, 2003). In the present study, we first analyzed the function of those manufactured e-RBCs in comparison of that of adult peripheral blood RBCs (PB-RBCs) or that of eryhthroblasts. The hemoglobin (Hb) content of the e-RBCs quantified by photometric determination was almost equivalent to that of adult PBRBC. A Hb A/Hb F ratio of e-RBC analyzed by high-performance liquid chromatography (HbA: HbF = 35: 65) was between those of CB RBCs (10: 90) and adult PB-RBC (99: 1). Oxygen dissociation curves of e-RBCs measured by Hemox-Analyzer was comparable to that of fresh adult PB-RBCs. The erythroblasts showed adhesive property to stromal cells in vitro but e-RBC did not. When we injected e-RBCs into NOD/SCID mice, they were detectable in circulation while erythroblasts were not. In conclusion, the e-RBCs produced by large-scale culturing system from CB CD34+ cells may be useful for acute blood loss.


Cytotherapy ◽  
2013 ◽  
Vol 15 (11) ◽  
pp. 1374-1384 ◽  
Author(s):  
Na Xiao ◽  
Xiuhua Zhao ◽  
Pan Luo ◽  
Jinpeng Guo ◽  
Qian Zhao ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4104-4104
Author(s):  
Ora Burger ◽  
Osnat M. Jacov ◽  
Nirit D. Carmi ◽  
Galit F. Ashtamker ◽  
Lena Pinzur ◽  
...  

Abstract The use of human umbilical cord blood (hUCB) for transplantation (CBT) in adults is limited due to the low cell number in each unit. Engraftment rates are lower and the time to neutrophils and platelet recovery is longer following CBT compared to bone marrow (BM) transplantation (28 vs 14 days, respectively). Co-transplantation of human hematopoietic stem/progenitor cells (hHSC) with mesenchymal stromal cells in an irradiated NOD/SCID mice model has been demonstrated to promote HSC engraftment. In a typical clinical setting of CBT, unfractionated cord blood cells (UFCBC) are usually used. On the other hand, in the irradiated NOD/SCID mice model, the CD34+ enriched fraction is usually used. Therfore, performing pre-clinical studies using UFCBC would better reflect the outcome in the clinical setting. Using PluriX technology, we expanded human placental derived mesenchymal stromal cells on 3D carriers in a bioreactor (PLX-I) and evaluated their potential to promote the engraftment of UFCBC or hUCB derived fractionated CD34+ cells (hCD34+) in NOD/SCID mice. UFCBC (107) or hCD34+ (5×104) were injected into the tail vein of 7–8 week old NOD/SCID mice along with 0.5×106 or 1×106 PLX-I cells. Following 5–6 weeks, FACS analysis of % human CD45+ cells in mice BM demonstrated that in the PLX-I untreated mice, the 107 UFCBC engrafted in a lower rate compare to 5*104 hCD34+ (6.28% vs. 14.43% respectively, n=10). Furthermore, in both settings, hCD34+ and UFCBC, the addition of PLX-I enhanced the hHSC engraftment 1.7 and 2 fold respectively compared to PLX-I untreated mice (24.13% vs. 14.43% in hCD34+ setting and 12.85% vs. 6.28% in UFCBC setting, n=10). We conclude that UFCBC can be used for hHSC engraftment in NOD/SCID mice model and co-transplantation of these cells with PLX-I may serve as a promising approach for the improvement of the hitherto delayed engraftment following cord blood transplantation.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3465-3465 ◽  
Author(s):  
Zygmunt Pojda ◽  
Eugeniusz K Machaj ◽  
Marzena Korczak ◽  
Aleksandra Kopera ◽  
Paulina Adamczyk-Wojciechowska ◽  
...  

Abstract Project design and rationale: Expanding clinical evidence suggests, that combined transplantation of allogeneic hematopoietic stem cells (HSC) and mesenchymal stromal cells (MSC) improves the results when compared to the transplantation of HSC only by the enhancement of engraftment or reduction of the frequency and gravity of graft versus host (GVH) disease. We have modified our method [1] of the processing and liquid nitrogen–storage of umbilical cord stromal cells (UCSC, the analogue of adult bone marrow MSC) for the combined collection and banking of cord blood hematopoietic stem cells (CB HSC) and UCSC obtained from the same donor for the hematopoietic transplantation purposes. Practical outcome of the project is the availability of cryopreserved combinations of cord blood samples plus the same donor-derived fetal MSC-type cells for clinical applications. Methods: Cord blood (CB) samples were collected and processed according to the routine protocol of Warsaw cord blood bank. Cord blood samples (vol.≥90 ml) were collected before or after placenta delivery, and viability and sterility-tested suspensions of mononuclear cells were volume-reduced and frozen in 10% DMSO/5% albumin using controlled-rate freezer, and stored in liquid nitrogen storage tanks. Umbilical cords, collected from the same deliveries as CB, were transported for processing in sterile balanced salt solution (PBS) supplemented with Penicillin/Streptomycin (22–25°C, time until processing ≤24h). Following mounting on the dissecting table, they were cut into 7 cm pieces, and surgically dissected in sterile conditions. After removal of cord amnion and blood vessels, Wharton jelly was cut into strips of thickness < 2 mm, sealed in 2 freezing bags in 10% DMSO/5%albumin and frozen in control-rate freezer. For experimental purposes, another strip of Wharton jelly was frozen in third bag, stored for 14 days, thawed, and the UCSC were in vitro expanded throughout consecutive 5 passages, phenotype-analysed, and tested for their ability for adipo-chondro-, and osteogenesis. Remaining fragments of umbilical cord (blood vessels, Wharton jelly pieces) were sterility-tested, and the contaminated frozen samples were eliminated at the quarantine stage. Maternal blood examination, HLA-typing, family history analysis etc. obligatory tests for CB banking were done only once, and the results were valid both for CB HSC and UCSC, reducing the labor time and costs of tests. Results: Both in cord blood samples, and umbilical cords, the frequency of bacterial/fungal infections was <1.5%, and viability of cells was>99%. The frequency of successful expansion of frozen/thawed UCSC was >90%, and average UCSC number after expansion was 2.5× 1011cells. All UCSC were plastic adherent, expressed CD34−, CD45−, Lin1−, CXCR4−, CD29+, CD73+, CD90+, CD105+ surface markers, and were able to differentiate into adipo-, chondro-, and osteogenic lineages, thus confirming their MSC characteristics. Before the full validation of the procedures, CB HSC and UCSC obtained from the same donor are stored in Warsaw cord blood bank in separate storage tanks in −170°C in liquid nitrogen vapors. If the transplantation of cord blood cells plus umbilical cord MSC-like cells will be accepted as the standard clinical protocol, the double cassette for combined CB HSC/UCSC storage will be implemented. Conclusion: The practical result of the presented study is the implementation of the new protocol allowing for availability of cord blood cells and mesenchymal stromal cells from the same donor for clinical transplantation purposes.


Transfusion ◽  
2008 ◽  
Vol 48 (10) ◽  
pp. 2235-2245 ◽  
Author(s):  
Eun Jung Baek ◽  
Han-Soo Kim ◽  
Sinyoung Kim ◽  
Honglien Jin ◽  
Tae-Yeal Choi ◽  
...  

2012 ◽  
Vol 318 (4) ◽  
pp. 400-407 ◽  
Author(s):  
Francesca Vulcano ◽  
Luisa Milazzo ◽  
Carmela Ciccarelli ◽  
Alessandra Barca ◽  
Francesca Agostini ◽  
...  

Blood ◽  
2000 ◽  
Vol 96 (13) ◽  
pp. 4169-4177 ◽  
Author(s):  
Adeline Lepage ◽  
Marylène Leboeuf ◽  
Jean-Pierre Cazenave ◽  
Corinne de la Salle ◽  
François Lanza ◽  
...  

Abstract Megakaryocytopoiesis is a complex multistep process involving cell division, endoreplication, and maturation and resulting in the release of platelets into the blood circulation. Megakaryocytes (MK) progressively express lineage-restricted proteins, some of which play essential roles in platelet physiology. Glycoprotein (GP)Ib-V-IX (CD42) and GPIIb (CD41) are examples of MK-specific proteins having receptor properties essential for platelet adhesion and aggregation. This study defined the progressive expression of the GPIb-V-IX complex during in vitro MK maturation and compared it to that of GPIIb, an early MK marker. Human cord blood CD34+ progenitor cells were cultured in the presence of cytokines inducing megakaryocytic differentiation. GPIb-V-IX expression appeared at day 3 of culture and was strictly dependent on MK cytokine induction, whereas GPIIb was already present in immature CD34+ cells. Analysis by flow cytometry and of the messenger RNA level both showed that GPV appeared 1 day later than GPIb-IX. Microscopy studies confirmed the late appearance of GPV, which was principally localized in the cytoplasm when GPIb-IX was found on the cell surface, suggesting a delayed program of GPV synthesis and trafficking. Cell sorting studies revealed that the CD41+GPV+ population contained 4N and 8N cells at day 7, and was less effective than CD41+GPV− cells in generating burst-forming units of erythrocytes or MK colonies. This study shows that the subunits of the GPIb-V-IX complex represent unique surface markers of MK maturation. The genes coding for GPIb-IX and GPV are useful tools to study megakaryocytopoiesis and for tissue-specific or conditional expression in mature MK and platelets.


Sign in / Sign up

Export Citation Format

Share Document